A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in Pacira Pharmaceuticals by 1.6% in the fourth quarter. Renaissance Technologies LLC now owns 25,200 shares of the company’s stock valued at $814,000 after buying an additional 400 shares during the last quarter. American International Group Inc. boosted its position in Pacira Pharmaceuticals by 5.3% in the first quarter. American International Group Inc. now owns 22,060 shares of the company’s stock valued at $1,006,000 after buying an additional 1,103 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock valued at $114,000 after buying an additional 1,149 shares during the last quarter. Swiss National Bank boosted its position in Pacira Pharmaceuticals by 2.5% in the first quarter. Swiss National Bank now owns 61,300 shares of the company’s stock valued at $2,795,000 after buying an additional 1,500 shares during the last quarter. Finally, Suntrust Banks Inc. boosted its position in Pacira Pharmaceuticals by 19.8% in the first quarter. Suntrust Banks Inc. now owns 14,437 shares of the company’s stock valued at $658,000 after buying an additional 2,385 shares during the last quarter.
TIAA CREF Investment Management LLC increased its stake in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 25.8% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 136,167 shares of the company’s stock after buying an additional 27,942 shares during the period. TIAA CREF Investment Management LLC owned about 0.36% of Pacira Pharmaceuticals worth $6,209,000 as of its most recent filing with the SEC.
Pacira Pharmaceuticals, Inc. (PCRX) traded down 1.92% during mid-day trading on Wednesday, hitting $38.40. The stock had a trading volume of 1,508,694 shares. Pacira Pharmaceuticals, Inc. has a 12-month low of $29.95 and a 12-month high of $58.95. The firm’s market cap is $1.54 billion. The company has a 50-day moving average of $46.37 and a 200-day moving average of $45.57.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative return on equity of 7.71% and a negative net margin of 19.26%. The company had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. During the same period in the previous year, the business posted $0.21 EPS. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts expect that Pacira Pharmaceuticals, Inc. will post ($0.02) earnings per share for the current year.
A number of brokerages have issued reports on PCRX. HC Wainwright set a $59.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 6th. Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a report on Wednesday. BidaskClub downgraded Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday. Royal Bank Of Canada began coverage on Pacira Pharmaceuticals in a report on Thursday, April 13th. They set an “outperform” rating and a $58.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, June 21st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. Pacira Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $54.92.
In other Pacira Pharmaceuticals news, President James S. Scibetta sold 20,000 shares of the firm’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $51.20, for a total value of $1,024,000.00. Following the transaction, the president now owns 47,084 shares of the company’s stock, valued at $2,410,700.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kristen Marie Williams sold 21,041 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $50.86, for a total transaction of $1,070,145.26. Following the completion of the transaction, the chief accounting officer now directly owns 18,775 shares in the company, valued at approximately $954,896.50. The disclosure for this sale can be found here. Insiders have sold 50,564 shares of company stock worth $2,506,682 in the last ninety days. Corporate insiders own 6.60% of the company’s stock.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.